Iambic Therapeutics (IAM Proposed) and City Therapeutics (CTY Proposed) are in the spotlight this week as the only two deals on the IPO Calendar so far. Both biotechs are set to g ...

Eli Lilly owned a pre-IPO stake in TRex Bio that was the equivalent of 23.9 percent of the biotech’s outstanding stock; that stake was set to decline to 16.8 percent of TRex Bio’s outstanding shares ...

Iambic Therapeutics (IAM Proposed), a biotech targeting breast cancer and lung cancer, unveiled the terms for its $150 million IPO early today and launched the deal for pricing next week. The company ...

Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums), is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might ...

We are a medical device company preparing to commercialize breakthrough computerized analysis technology that enhances clinicians’ capabilities in diagnosing neurological and neurodevelopmental ...

TRex Bio (TRXB Proposed), an Eli Lilly-backed biotech, unveiled the terms for its $125 million IPO early today: 8.33 million shares at a price range of $14.00 to $16.00 to raise $124.95 million, if ...

We are a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on ...

Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums), is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might ...

We are a newly organized blank check company. We intend to focus our search for an acquisition target on companies involved in agentic AI, stablecoin payments and digital yield platforms. Norma Chu is ...

Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums), is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might ...